Nonetheless, the fact that HDAC inhibitors have already been exploited as therapeutic strategies for hematologic malignancies raises intriguing possibilities for further studies aiming at other cancer types expressing deregulated MYC [83,84,85]. The gene discussed is HDAC9; the disease is cancer.